KYMR•benzinga•
Stephens & Co. Initiates Coverage On Kymera Therapeutics with Overweight Rating, Announces Price Target of $65
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on November 18, 2024 by benzinga